Health Trials

Relapsed Rhabdomyosarcoma

1

Review clinical trials related to Relapsed Rhabdomyosarcoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B). The phase 2 primary objective is to estimate the objective response rate (ORR) in children with refractory, progressive and relapsed NBL and rhabdomyosarcoma (RMS) treated with the RP2D of PEEL-224 in combination with vincristine and temozolomide.

Participants needed: 59
Trial details
Phase: Phase 1, Phase 2Age: 1-30Biological sex: AllType: InterventionalSponsor: Theodore LaetschUpdated: Jun 15, 2026Locations: 7
Eligibility criteria

Phase 1: Age greater than or equal to 1 year and less than or equal to18 years [+39]

Prior treatment with PEEL-224. [+6]

Read more